| 查看: 291 | 回复: 2 | |||
| 当前主题已经存档。 | |||
guoningli金虫 (小有名气)
|
[交流]
汉译英
|
||
| 学科交叉优势互补:本课题为药理学和药物化学交叉研究课题,其中的化合物设计工作是在对金属蛋白酶结构及其周围环境进行充分研究基础上,发挥生物信息学和生物计算技术优势,通过计算机分子动力学模拟、虚拟筛选、定向合成、体内外活性筛选和定量构效关系等环节优化筛选合成的。这是一类全新结构和作用机制的化合物,如果开发成功,不仅将成为第一个具有自主知识产权的新结构慢性肝病防治药物,对于未来研究开发同类型的新药提供生物信息资源。 |
» 猜你喜欢
极限拉扯,如何抉择
已经有8人回复
入职后第一次管课题组的专利缴费,对账才发现官费比别人多掏了一倍
已经有6人回复
OpenAI又攻克数学难题了,离AI做有机合成还有多远?
已经有8人回复
课题组会帮你通过考核么?
已经有6人回复
售一区SCI文章T0P,我:8O.551.O54,科目全,可十急
已经有9人回复
售SCI一区T0P文章,我:8.O55.1.O.54,科目全,可十急
已经有8人回复
售SCI一区文章,我:8O5.5.1.O5.4,科目全,可伽急
已经有10人回复
售SCI一区T0P文章,我:8.O55.1.O.54,科目全,可十急
已经有9人回复
售SCI一区文章,我:8.O.55.1.O.54,科目齐全,可伽急
已经有7人回复
售SCI文章,我:8O5.5.1.O.54,科目齐全,可+急
已经有10人回复
★ ★ ★ ★ ★ ★ ★ ★ ★ ★
guoningli(金币+6,VIP+0): 12-25 19:32
zap65535(金币+4,VIP+0):补发 12-28 10:52
guoningli(金币+6,VIP+0): 12-25 19:32
zap65535(金币+4,VIP+0):补发 12-28 10:52
|
Interdisciplinary Subjects and Complemented Strengths: This research is a interdisciplinary subject studying on pharmacology and pharmaceutical chemistry, where based on the sufficient studies on the structure of the metal protease and its surrounding environment, research of new compounds designing is been done by taking the advantage of of bio-informatics and bio-computing technologies through the optimized and selective synthesis including the molecular dynamics simulation with computer, virtual selection, directed synthesis, selecting by in-vivo or in-vitro activities and quantitative structure-activity relationship respectively. This is completely a new kind of compound with novel structure and mechanism. If successfully developed, it will become not only the first new entity drug for treatment and prevention of chronic liver disease with independent intellectual property rights, but also a good example for the following new brother drugs coming out from the development in the future by providing the biological information resources. |
2楼2009-12-23 16:43:34
guoningli
金虫 (小有名气)
- 应助: 0 (幼儿园)
- 金币: 1181.1
- 散金: 2
- 红花: 1
- 帖子: 176
- 在线: 20.6小时
- 虫号: 746571
- 注册: 2009-04-12
- 专业: 合成药物化学
3楼2009-12-25 19:31:50










回复此楼